Overview of a Phase I clinical trial using BGB-3111 for the treatment of relapsed CLL
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
Overview of the clinical trial of ibrutinib vs chlorambucil as front-line therapy